- $6.47bn
- $6.04bn
- $1.18bn
U.S. STOCKS ON THE MOVE-Dynatrace, Cava Group, Halozyme Therapeutics
U.S. STOCKS ON THE MOVE-Halozyme Therapeutics, Etsy, Netflix
Cava rises after announcing $100 million share repurchase plan
U.S. RESEARCH ROUNDUP-Domino's, McDonald's, Starbucks
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
U.S. STOCKS ON THE MOVE-Nebius Group, Lumentum Holdings
Cava Group jumps on Q2 sales growth, profit beat
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Cava Group, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary
Cava jumps after upbeat quarterly results
Cava cites prudence in keeping forecast unchanged after quarterly beat (updated)
CAVA Q2 revenue beats analyst expectations on traffic increase, restarurant openings
Brief: CAVA Group Q2 Revenue USD 368.436 Million Vs. IBES Estimate USD 360.5 Million
Cava beats quarterly expectations, reiterates forecasts amid outbreaks and economic worries
For McDonald's and rivals, cheap deals no longer do the trick (updated)
For McDonald's and rivals, cheap deals no longer do the trick
Corrected: UPDATE 3-US FDA continues investigating Taylor Farms as cyclosporiasis cases mount (July 20)
Sandwich-shop IPO depends on hero worship